FDA Generic Drug User Fee Rates: Fiscal Year 2019

August 7, 2018

FDA Updates Generic Drug User Fee Rates for FY 2019

On Friday, July 27th, FDA released a notice with updated generic drug user fee rates for fiscal year 2019. Under GDUFA II, user fees should total $493,600,000 each year, adjusted for inflation. The updated fees are effective October 1, 2018 through September 30, 2019.

Generic Drug Fee Rates

Fee Category FY 2019 Fee Rates
ANDA Filing $178,799
DMF $55,013
Domestic FDF $211,305
Foreign FDF $226,305
Domestic CMO $70,435
Foreign CMO $85,435
Domestic API Facility $44,226
Foreign API Facility $59,226
Generic Drug Applicant (Large Business) $1,862,167
Generic Drug Applicant (Medium Business) $744,867
Generic Drug Applicant (Small Business) $186,217

ANDA Filing Fee

Any applicant submitting an ANDA after October 1st, 2018 will owe the updated FY 2019 fee, which is due on the ANDA’s submission date. The FY 2019 ANDA fee was calculated by dividing the number of full application equivalents (FAEs) into the revenue from ANDA application fees. The FY 2019 ANDA filing fee is $178,799.


Anyone who owns a type II active pharmaceutical ingredient DMF that is referenced in a generic drug submission on or before October 1, 2012, owes a DMF fee.  “This fee is due on the earlier of the date on which the first generic drug submission is submitted that references the associated DMF or the date on which the drug master file holder requests the initial completeness assessment.” This is a one-time fee (for each DMF), and the FY 2019 DMF fee was calculated by dividing the total DMF target revenue by the estimated number of fee-paying DMFs. The FY 2019 DMF fee is $55,013.

Foreign Facility Fee Differential

Due to higher inspection costs, facilities located outside of the United States owe an additional $15,000 in facility fees.

FDF & CMO Facility Fees

According to Section 744B(b)(2)(c) of the FD&C Act, FDF and CMO facility fees are to make up 20% of total revenue, or $100,344,200. Under GDUFA II, the CMO facility fee should be 1/3 the amount of the FDF facility fee. Therefore, for FY 2019, the domestic CMO fee is $70,435 and the domestic FDF facility fee is $211,305. If the facility is not located in the United States or its territories, an additional $15,000 fee applies.

API Facility Fee

Anyone who owns a facility that has been identified in at least one approved generic drug submission or in a Type II API DMF referenced in at least one approved generic submission owes an API facility fee. The FY 2019 API facility fee is $44,226 while the foreign API fee is $59,226.  

Generic Drug Applicant Program Fee

The generic drug applicant program fee depends on the size of the business, which is determined by the total number of approved ANDAs a company has.

  • Small Business: 1-5 approved ANDAs, owe $186,217
  • Medium Size Operation: 6-19 approved ANDAs, owe $744,867
  • Large Size Operation: 20+ approved ANDAs, owe $1,862,167

Large companies pay the full program fee, while medium sized operations pay two-fifths of the full fee and small businesses pay one-tenth of the full fee.

Are you in the process of developing a generic drug? Do you need help preparing and submitting your ANDA to the FDA? We can help. Contact us today to learn more about our services and how we can help you obtain approval from the Agency.


August 7, 2015

FDA Generic Drug User Fee Rates: Fiscal Year 2016

As required by the Generic Drug User Fee Amendments of 2012, FDA has announced the 2016 rates for the following user fees: Abbreviated new drug application (ANDA), Prior approval to an ANDA (PAS),...

August 4, 2016

FDA Generic Drug User Fee Rates: Fiscal Year 2017

FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...

September 29, 2023

Navigating FDA User Fee Updates for Fiscal Year 2023

As the U.S. Government begins its fiscal year on October 1, it signifies the annual revisions in FDA User Fees, which have an impact on applications and facilities associated with Prescription Drugs...